Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Hereditary angioedema" patented technology

Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling. The swelling most commonly affects the arms, legs, face, intestinal tract, and airway. Itchiness does not typically occur. If the intestinal tract is affected abdominal pain and vomiting may occur. Swelling of the airway can result in its obstruction. Attacks, without preventive treatment, typically occur every couple of weeks and last for a few days.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
Owner:TAKEDA PHARMA CO LTD

Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.
Owner:TAKEDA PHARMA CO LTD

Compositions and Methods for Inhibition of Factor XII Gene Expression

RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
Owner:ARROWHEAD PHARMACEUTICALS INC

Bispecific antibodies against plasma kallikrein and factor XII

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
Owner:TAKEDA PHARMA CO LTD

A composition comprising factor XII (Hagemann factor) (F12), kallikrein B, plasma (Fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA, and a method for using the same.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.
Owner:ALNYLAM PHARMACEUTICALS INC

RNA biomarkers for hereditary angioedema

To provide methods for identifying a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.SOLUTION: A method for analyzing a sample includes measuring the level of a RNA biomarker set including at least one RNA biomarker disclosed herein.SELECTED DRAWING: None
Owner:TAKEDA PHARMA CO LTD

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
Owner:TAKEDA PHARMA CO LTD

Heteroaromatic formamide compound and application thereof in medicine

The invention relates to a heteroaromatic formamide compound and application thereof in medicine. Specifically, the invention relates to a heteroaromatic formamide compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound as a therapeutic agent for plasma kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins and kallikins. The present invention relates to the use of a PKa selective inhibitor and to the use in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, in particular for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, and the like, and more particularly to the use in the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, etc. # imgabs0 #
Owner:LONGWOOD PHARMACEUTICALS (HANGZHOU) CO LTD

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

ActiveUS12338439B2Organic active ingredientsSugar derivativesContact activationKinin
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.
Owner:ALNYLAM PHARMACEUTICALS INC

N-carbohydrate chain marker for predicting seizure part of type 2 hereditary angioedema, kit and application of N-carbohydrate chain marker

The invention relates to the technical field of medical detection, in particular to an N-carbohydrate chain marker for predicting a seizure site of type 2 hereditary angioedema, a kit and application of the N-carbohydrate chain marker. In the N-carbohydrate chain marker provided by the invention, the contents of H6N5F1E2L1 and H5N4F1E1L1 are remarkably changed in the body of a patient suffering from laryngeal edema, and H3N3F1, H6N3E1 and H5N2 are remarkably changed in the body of a patient suffering from abdominal edema, so that the N-carbohydrate chain marker shows relatively good seizure site identification capability of type 2 hereditary angioedema, and the seizure site identification capability of type 2 hereditary angioedema is remarkably improved. The kit has high specificity, sensitivity and accuracy. The N-carbohydrate chain marker has the advantages of being convenient to detect, short in required time and the like when being used for predicting the site of attack, and has important significance for giving personalized prevention and treatment measures in time.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Factor xii (hageman factor) (F12), kallikrein b, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) IRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.
Owner:ALNYLAM PHARMACEUTICALS INC

Compositions and methods for kallikrein (KLKB1) gene editing

ActiveUS12781209B2KininHereditary angioedema
Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.
Owner:INTELLIA THERAPEUTICS INC

Plasma kallikrein-binding protein in treatment of hereditary angioedema and use thereof

To provide a method for treating hereditary angioedema.SOLUTION: The present invention provides a plasma kallikrein-binding protein such as an antibody binding to active plasma kallikrein in the treatment of hereditary angioedema, and a method for using the protein.SELECTED DRAWING: Figure 11
Owner:TAKEDA PHARMA CO LTD

Compositions and methods for inhibiting factor XII gene expression

The present disclosure relates to compositions and methods for inhibiting factor XII gene expression. RNA interfering substances for inhibiting expression of the Factor XII (FXII) gene are described. Also described are pharmaceutical compositions comprising one or more FXII RNAi substances and one or more excipients capable of delivering the RNAi substances to hepatocytes in vivo. Delivery of the FXII RNAi substance to hepatocytes in vivo provides inhibition of FXII gene expression and inhibition of angioedema, including hereditary angioedema (HAE), venous thromboembolism (VTE), and diseases associated with angioedema.
Owner:ARROWHEAD PHARMACEUTICALS INC

Bispecific antibodies against plasma kallikrein and factor xii

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
Owner:TAKEDA PHARMA CO LTD

Therapeutic compounds and compositions

To provide therapeutic compounds and compositions.SOLUTION: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable salts thereof and compositions, and methods of use thereof. The present invention features compounds that inhibit Factor XIa or kallikrein and methods for preventing or treating undesired thrombosis or angioedema (e.g., hereditary angioedema) by administering one or more of these compounds alone or in combination with other molecules to a mammal.SELECTED DRAWING: None
Owner:EXITHERA PHARMACEUTICALS INC

Oral sebetralstat for the treatment of an attack of hereditary angioedema

The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering the plasma kallikrein inhibitor sebetralstat to a patient in need thereof on-demand.
Owner:KALVISTA PHARMA

Plasma-calcium binding proteins and uses in the treatment of hereditary angioedema

ActiveDE602015092785T2Antibody ingredientsImmunoglobulinsCalcium-binding proteinPlasma calcium
Owner:TAKEDA PHARMA CO LTD

Method and system for processing hereditary angioedema symptom data

The invention relates to the technical field of medical data processing, and provides a hereditary angioedema symptom data processing method and system, and the method comprises the steps: obtaining symptom data to be processed; extracting a symptom feature vector of the symptom data to be processed; inputting the symptom feature vector into a disease probability prediction model to obtain the probability of having hereditary angioedema output by the disease probability prediction model; wherein the illness probability prediction model is obtained based on sample symptom data and illness probability truth value label training corresponding to the sample symptom data. According to the method, the disease probability prediction model is trained through the sample symptom data and the corresponding labels, and then the disease probability prediction model is used for predicting the symptom data to be processed of the patient to be diagnosed, so that the probability of suffering from hereditary angioedema is obtained for reference diagnosis of doctors, and final definite diagnosis is facilitated.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Plasma kallikrein inhibitors and their use in treating hereditary angioedema attacks

ActiveJP7894905B2KininDepressant
To provide methods for treating hereditary angioedema (HAE) attacks or reducing the rate of HAE attacks.SOLUTION: Provided is a composition comprising an antibody capable of binding to and inhibiting active human plasma kallikrein (pKal), the composition being administered such that the antibody is administered to a human subject multiple times at about 300 mg every two weeks during a first treatment period, the human subject having, being suspected of having, or being at risk for HAE, the human subject (i) being female; (ii) being under 18 years of age or between 40 and 65 years of age; (iii) having had at least one previous attack of laryngeal HAE; (iv) having had 1-2, 2-3, or 4 or more attacks of HAE in the four weeks prior to the first administration of the first treatment period; and / or (v) having been treated with a C1-inhibitor prior to the first treatment period.SELECTED DRAWING: Figure 1
Owner:TAKEDA PHARMA CO LTD

Application method of multiple sites of SERPING1 gene in genetic disease detection

An application method of multiple sites of an SERPING1 gene in genetic disease detection belongs to the technical field of detection, and comprises five steps of DNA extraction, DNA amplification, DNA purification, delivery sequencing and information analysis. DNA extraction comprises 12 sub-steps, and DNA amplification comprises two sub-steps; dNA purification comprises seven sub-steps, and delivery sequencing is as follows: a DNA solution is delivered to a sequencing service provider, a primer is used for DNA sequencing, and a sequence containing pathogenic SNP site base information on an SERPING1 gene in sample DNA is measured; and the raw information analysis comprises two sub-steps. According to the invention, the SNP sites can be subjected to first-generation sequencing, the site variation condition can be obtained, the result is applied to preparation of products for detecting or screening hereditary angioedema, the detection range is wide, the success rate is high, and the problems that in the prior art, a plurality of pathogenic SNP sites on the SERPING1 gene are not recorded by the existing pathogenic site information base, and the detection result is poor are solved. And misdiagnosis or treatment delay can be caused by the fact that the important pathogenic variation is not identified, so that the rehabilitation condition of the patient is influenced.
Owner:MUEN (WUHAN) MEDICAL & BIOTECHNOLOGY CO LTD